Your browser doesn't support javascript.
loading
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
Fizazi, Karim; González Mella, Pablo; Castellano, Daniel; Minatta, Jose N; Rezazadeh Kalebasty, Arash; Shaffer, David; Vázquez Limón, Juan C; Sánchez López, Héctor M; Armstrong, Andrew J; Horvath, Lisa; Bastos, Diogo A; Amin, Neha P; Li, Jia; Unsal-Kacmaz, Keziban; Retz, Margitta; Saad, Fred; Petrylak, Daniel P; Pachynski, Russell K.
Affiliation
  • Fizazi K; Department of Cancer Medicine, Gustave Roussy, University Paris Saclay, Villejuif, France. Electronic address: Karim.fizazi@gustaveroussy.fr.
  • González Mella P; Department of Radiotherapy, Fundación Arturo López Pérez, Santiago, Chile.
  • Castellano D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Minatta JN; Department of Oncology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Rezazadeh Kalebasty A; Department of Medical Oncology, Norton Cancer Institute, Louisville, KY, USA.
  • Shaffer D; Department of Medical Oncology, New York Oncology Hematology, Albany, NY, USA.
  • Vázquez Limón JC; Department of Medical Oncology, Instituto Jalisciense de Cancerología, Guadalajara, Mexico.
  • Sánchez López HM; Department of Urological Oncology, Hospital Regional de Alta Especialidad del Bajío, Guanajuato, Mexico.
  • Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
  • Horvath L; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
  • Bastos DA; Department of Oncology, Hospital Sirio-Libanes, São Paulo, Brazil.
  • Amin NP; Department of Clinical Oncology, Bristol Myers Squibb, Princeton, NJ, USA.
  • Li J; Department of Biostatistics, Bristol Myers Squibb, Princeton, NJ, USA.
  • Unsal-Kacmaz K; Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA.
  • Retz M; Department of Urology, Rechts der Isar Medical Center, Technical University Munich, Munich, Germany.
  • Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal/CHUM, Montreal, QC, Canada.
  • Petrylak DP; Smilow Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Pachynski RK; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Eur J Cancer ; 160: 61-71, 2022 01.
Article de En | MEDLINE | ID: mdl-34802864
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Tumeurs prostatiques résistantes à la castration / Docetaxel / Nivolumab Type d'étude: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Aged / Aged80 / Humans / Male / Middle aged Langue: En Journal: Eur J Cancer Année: 2022 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Tumeurs prostatiques résistantes à la castration / Docetaxel / Nivolumab Type d'étude: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Aged / Aged80 / Humans / Male / Middle aged Langue: En Journal: Eur J Cancer Année: 2022 Type de document: Article